tirzepatide injectable FDA Grants a New Indication for Obesity Management Most Successful Weight Loss Program. Semaglutide & Tirzepatide Dosing Guide:

Efficacy results of SUSTAIN-2, 3, and 4 in the overall population are presented in Appendix 4

Purity: 99% per component by HPLC, verified per batch by Janoshik Analytical against the two expected molecular masses

The clinics dedication to individualized care, combined with the use of the latest medications like semaglutide and tirzepatide, ensures that each client has the tools and support needed to achieve and maintain their weight loss goals

Adverse Reactions in Clinical Trials in Adults with Obesity or Overweight for Weight Reduction WEGOVY 2.4 mg Subcutaneous Weekly Dosage WEGOVY was evaluated for safety in 3 randomized, double-blind, placebo-controlled trials that included 2,116 adult patients with obesity or overweight treated with 2.4 mg WEGOVY for up to 68 weeks and a 7-week offdrug follow-up period [see Clinical Studies (14.2)]

It is commonly used in the treatment of diabetes mellitus

Additional studies have shown similar results, according to a UCLA article on the subject